Bio Briefs
Posted By
Recent Posts on This Topic | See All >
-
Feb 07, 2012 Support grows for medical-device community -
Dec 19, 2011 BioAccel launches network to attract bio funding
-
Jul 19, 2011 Cardinal Health opens $11M Phoenix facility
-
Apr 07, 2011 Algae Biosciences Corp. taken public
Share on Twitter
Share on Facebook
Email to a friend
Print Article
ImmuneRegen initiates efficacy studies of anti-influenza drug
[Source: Trading Markets] - ImmuneRegen BioSciences, a wholly owned subsidiary of IR Biosciences Holdings, has reported that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 avian influenza in the laboratories of a university scientist.
The newly recognized H1N1-2009 influenza virus is also highly infectious, having spread throughout the world in a matter of months with a slightly higher lethality of 0.4% (mostly healthy younger individuals with no prior exposure, or therefore immunity, to this virus type). Early outbreaks of avian influenza (H5N1) in 2006, 2007 and 2008 were relatively contained but with very high lethality of 69%, 67% and 75%, respectively, said ImmuneRegen.
For more information: ImmuneRegen initiates efficacy studies of anti-influenza drug
Quick Links
- NEW: About the Arizona Center for Civic Leadership
- Arizona Biosciences News
- Arizona BioMap
- Roadmap Progress Updates
- Reports & Multimedia
- Timeline: Arizona's Bio Growth
- Arizona Bio Orgs on Twitter
- Arizona BioBasics
- The Biozona Brand
- Newsletter Signup
Download a new brochure from the Flinn Foundation outlining the 2011 progress on Arizona's Bioscienced Roadmap: a record high in bioscience jobs, plus gains in firms and venture-capital funding. Numerous achievements during the year advanced the core strategies of the Roadmap.
Also, read the full Performance Assessment describing in detail Arizona's 2011 progress on key Roadmap metrics.
